Johnson & Johnson (NYSE:JNJ) has been assigned an average rating of “Hold” from the twenty-two research firms that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $145.33.

Several research firms recently issued reports on JNJ. Citigroup upped their target price on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Vetr raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a research report on Monday, October 30th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BMO Capital Markets upped their target price on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Finally, Leerink Swann reissued an “outperform” rating and issued a $165.00 target price (up from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th.

Johnson & Johnson (NYSE:JNJ) opened at $140.12 on Tuesday. The stock has a market capitalization of $376,435.19, a price-to-earnings ratio of 24.33, a PEG ratio of 2.85 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the firm posted $1.68 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. equities research analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a $0.84 dividend. The ex-dividend date of this dividend was Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.40%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

Institutional investors have recently modified their holdings of the company. Harding Loevner LP bought a new position in Johnson & Johnson during the 2nd quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. Lenox Wealth Advisors Inc. increased its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the period. Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $177,000. Institutional investors and hedge funds own 65.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Receives Average Rating of “Hold” from Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/26/johnson-johnson-jnj-receives-average-rating-of-hold-from-analysts.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.